[go: up one dir, main page]

IN2014MN01495A - - Google Patents

Info

Publication number
IN2014MN01495A
IN2014MN01495A IN1495MUN2014A IN2014MN01495A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A IN 1495MUN2014 A IN1495MUN2014 A IN 1495MUN2014A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A
Authority
IN
India
Prior art keywords
metal
formula
group
mixed
patient
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Olof Karlsson
Karl Reineke
Tino Kurz
Rolf Andersson
Michael Hall
Christina Mclaughlin
Sven Jacobsson
Jacques Näsström
Original Assignee
Pledpharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pledpharma Ab filed Critical Pledpharma Ab
Publication of IN2014MN01495A publication Critical patent/IN2014MN01495A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C07F19/005Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN1495MUN2014 2012-01-05 2012-12-04 IN2014MN01495A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261583377P 2012-01-05 2012-01-05
US201261656178P 2012-06-06 2012-06-06
US201261668679P 2012-07-06 2012-07-06
US201261721575P 2012-11-02 2012-11-02
PCT/IB2012/056959 WO2013102806A1 (en) 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Publications (1)

Publication Number Publication Date
IN2014MN01495A true IN2014MN01495A (ru) 2015-04-17

Family

ID=47559596

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1495MUN2014 IN2014MN01495A (ru) 2012-01-05 2012-12-04

Country Status (15)

Country Link
US (3) US9187509B2 (ru)
EP (1) EP2800755B1 (ru)
JP (2) JP6131271B2 (ru)
KR (1) KR102086022B1 (ru)
CN (2) CN107353313B (ru)
AU (1) AU2012364227B2 (ru)
BR (1) BR112014016497B1 (ru)
CA (1) CA2862736C (ru)
ES (1) ES2683038T3 (ru)
HK (2) HK1203203A1 (ru)
IN (1) IN2014MN01495A (ru)
MX (1) MX2014008247A (ru)
RU (2) RU2622646C2 (ru)
WO (1) WO2013102806A1 (ru)
ZA (1) ZA201404904B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2622646C2 (ru) 2012-01-05 2017-06-19 Пледфарма Аб Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения
MX376321B (es) * 2012-11-02 2025-03-07 Egetis Therapeutics Ab Usos para el tratamiento de cancer.
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
JP7311267B2 (ja) * 2016-01-11 2023-07-19 エゲティス・セラピューティクス・アーベー 急性肝不全及び他の肝毒性状態を治療及び/又はこれらから保護するための方法及び製剤
WO2018087347A1 (en) * 2016-11-14 2018-05-17 Karlsson-Tuner Invest As Use of non-transition metal coordinated dipyridoxyl compounds to prevent and treat chemotherapy-induced psn
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Lttバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091169A (en) 1987-05-08 1992-02-25 Salutar, Inc. Dipyridoxyl phosphate NMRI contrast agent compositions
US5223243A (en) 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
AR246956A1 (es) * 1987-05-08 1994-10-31 Salutar Inc Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste.
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
GB9727224D0 (en) 1997-12-23 1998-02-25 Nycomed Imaging As Method
JP2001527072A (ja) 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10359628A1 (de) 2003-12-18 2005-07-21 Oxeno Olefinchemie Gmbh Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
WO2009078794A1 (en) 2007-12-14 2009-06-25 Pledpharma Ab Compounds for use in the treatment of cancer
US8414866B2 (en) * 2007-12-17 2013-04-09 Ge Healthcare As Method of magnetic resonance imaging of the heart with paramagnetic MN2+
EP2451457B1 (en) 2009-07-06 2018-03-07 Pledpharma AB Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
RU2622646C2 (ru) * 2012-01-05 2017-06-19 Пледфарма Аб Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения

Also Published As

Publication number Publication date
US20150005259A1 (en) 2015-01-01
HK1203203A1 (en) 2015-10-23
CN104169291A (zh) 2014-11-26
AU2012364227A1 (en) 2014-07-24
US20170165281A1 (en) 2017-06-15
AU2012364227B2 (en) 2017-12-07
RU2765805C2 (ru) 2022-02-03
MX2014008247A (es) 2015-03-09
BR112014016497A2 (pt) 2017-06-13
BR112014016497A8 (pt) 2017-07-04
JP6131271B2 (ja) 2017-05-17
RU2014132184A (ru) 2016-02-27
ZA201404904B (en) 2024-01-31
RU2622646C2 (ru) 2017-06-19
US9187509B2 (en) 2015-11-17
EP2800755B1 (en) 2018-05-30
RU2017119660A3 (ru) 2020-07-30
CN104169291B (zh) 2017-08-15
CA2862736C (en) 2020-09-08
JP2015504066A (ja) 2015-02-05
JP2017132801A (ja) 2017-08-03
RU2017119660A (ru) 2018-11-08
KR20140117480A (ko) 2014-10-07
KR102086022B1 (ko) 2020-03-06
JP6316479B2 (ja) 2018-04-25
CN107353313A (zh) 2017-11-17
EP2800755A1 (en) 2014-11-12
US9597334B2 (en) 2017-03-21
CN107353313B (zh) 2019-04-09
ES2683038T3 (es) 2018-09-24
US10111893B2 (en) 2018-10-30
WO2013102806A1 (en) 2013-07-11
HK1245276B (zh) 2020-05-08
US20160038507A1 (en) 2016-02-11
BR112014016497B1 (pt) 2021-02-23
CA2862736A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12015502839B1 (en) Antiviral compounds
IN2014MN01495A (ru)
EA201301154A1 (ru) Разветвленные производные 3-фенилпропионовой кислоты и их применение
MX362060B (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
MX2014001180A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015501316A1 (en) Heterocyclic compound
MX352928B (es) Compuestos de piridazina-amida.
MY170262A (en) Dicarboxylic acid compound
MX2014011921A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
IN2014CN04449A (ru)
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
GEP20166448B (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
PH12012501402A1 (en) Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
MY170637A (en) Macrocyclic compound and methods for its production
MX349548B (es) Compuestos de tienopirimidina.
JO3196B1 (ar) عملية تحضير ملح ل – ارجينين البيريندوبريل
MX357763B (es) Tratamiento para cancer pancreatico.
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
MX2012004914A (es) Compuestos de 2-aminoindol y metodos para el tratamiento de la malaria.